Correlation between the expression of folate receptor alpha (FRα) and clinicopathological features in patients with lung adenocarcinoma

Lung Cancer ◽  
2020 ◽  
Vol 145 ◽  
pp. 152-157 ◽  
Author(s):  
Nobumasa Tamura ◽  
Yutaka Fujiwara ◽  
Taiki Hashimoto ◽  
Hideaki Shiraishi ◽  
Shigehisa Kitano ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Folate Receptor ◽  
Clinicopathological Features ◽  
Folate Receptor Alpha ◽  
Receptor Alpha

scholarly journals Correlation between folate receptor alpha (FRα) expression and clinicopathological features in lung adenocarcinoma

2019 ◽  
Vol 30 ◽  
pp. ii2
Author(s):  
N. Tamura ◽  
Y. Fujiwara ◽  
T. Hashimoto ◽  
H. Shiraishi ◽  
S. Kitano ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Folate Receptor ◽  
Clinicopathological Features ◽  
Folate Receptor Alpha ◽  
Receptor Alpha

scholarly journals Decitabine Sensitizes the Radioresistant Lung Adenocarcinoma to Pemetrexed Through Upregulation of Folate Receptor Alpha

2021 ◽  
Vol 11 ◽  
Author(s):  
Yuqing Wang ◽  
Jie Huang ◽  
Qiong Wu ◽  
Jingjing Zhang ◽  
Zhiyuan Ma ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Folate Receptor ◽  
Critical Role ◽  
Subsequent Treatment ◽  
Folate Receptor Alpha ◽  
Fractionated Radiotherapy ◽  
Receptor Alpha ◽  
Regulatory Approach ◽  
Promising Treatment

Chemotherapy is the backbone of subsequent treatment for patients with lung adenocarcinoma (LUAD) exhibiting radiation resistance, and pemetrexed plays a critical role in this chemotherapy. However, few studies have assessed changes in the sensitivity of LUAD cells to pemetrexed under radioresistant circumstances. Therefore, the objectives of this study were to delineate changes in the sensitivity of radioresistant LUAD cells to pemetrexed and to elucidate the related mechanisms and then develop an optimal strategy to improve the cytotoxicity of pemetrexed in radioresistant LUAD cells. Our study showed a much lower efficacy of pemetrexed in radioresistant cells than in parental cells, and the mechanism of action was the significant downregulation of folate receptor alpha (FRα) by long-term fractionated radiotherapy, which resulted in less cellular pemetrexed accumulation. Interestingly, decitabine effectively reversed the decrease in FRα expression in radioresistant cells through an indirect regulatory approach. Thereafter, we designed a combination therapy of pemetrexed and decitabine and showed that the activation of FRα by decitabine sensitizes radioresistant LUAD cells to pemetrexed both in vitro and in xenografts. Our findings raised a question regarding the administration of pemetrexed to patients with LUAD exhibiting acquired radioresistance and accordingly suggested that a combination of pemetrexed and decitabine would be a promising treatment strategy.

Antibody-independent ApoStream technology isolates folate receptor alpha (FRA)–positive circulating tumor cells from blood of non-small cell lung adenocarcinoma patients.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e21028-e21028
Author(s):  
Darren W. Davis ◽  
Christopher Neal ◽  
Vishal Gupta ◽  
Vladislava O. Melnikova ◽  
Jacky Woo ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Folate Receptor ◽  
Small Cell ◽  
Normal Donor ◽  
Small Cell Lung ◽  
Folate Receptor Alpha ◽  
Receptor Alpha ◽  
Nsclc Patients

e21028 Background: The ability to enrich and interrogate circulating tumor cells (CTCs) from blood may allow for the analysis of metastatic dissemination and potential use of CTCs as surrogates for monitoring drug efficacy. We developed ApoStream, a dieletrophoresis field-flow fractionation based platform, for antibody-independent CTC isolation. We demonstrated that ApoStream successfully isolates non-small cell lung adenocarcinoma (NSCLC) CTCs that express Folate Receptor alpha (FRA), a GPI-anchored receptor, which has emerged as a cancer biomarker and potential therapeutic target in multiple cancer types. Methods: ApoStream technology was used to enrich CTCs from NSCLC patients’ blood. CTC enrichment by ApoStream was compared to that of the FDA cleared CellSearch CTC kit. A multiplexed immunofluorescent assay was developed to enable CTC enumeration (Cytokeratin+/CD45-/DAPI+ cells) and analysis of FRA expression (detection by murine antibody clone 26B3) using single cell quantitative laser scanning cytometry (LSC). Results: In a side-by-side comparison with the CellSearch CTC kit, ApoStream isolated significantly higher numbers of CTCs in 9 metastatic adenocarcinoma NSCLC patients (Apostream: mean =139, range 3-487 per 7.5 mL of blood, versus CellSearch kit: mean =2, range 0-8 per 7.5 mL of blood, n= 9, p=0.041). All patients were found to be CTC-positive by ApoStream, while only 3 of 9 (33%) patients were CTC-positive based on the CellSearch kit. LSC analysis demonstrated that 8-33% of all CTCs isolated expressed FRA and that FRA expression was confined to CTCs only. No false positive CTCs and no FRA-expressing cells were isolated by ApoStream from normal donor blood (n=15). Conclusions: All NSCLC adenocarcinoma patients analyzed had FRA-positive CTCs, suggesting that FRA may play a key role in metastasis and that screening of patients with the ApoStream CTC isolation system may identify patients who could benefit from FRA-targeted therapy.

A Novel Monoclonal Antibody for Detection of Folate Receptor Alpha in Paraffin-Embedded Tissues

Hybridoma ◽  
2007 ◽  
Vol 26 (5) ◽  
pp. 281-288 ◽  
Author(s):  
Amy E. Smith ◽  
Michael Pinkney ◽  
Nigel H. Piggott ◽  
Hilary Calvert ◽  
Ian D. Milton ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Folate Receptor ◽  
Folate Receptor Alpha ◽  
Receptor Alpha

T-Cell Immunity to the Folate Receptor Alpha Is Prevalent in Women With Breast or Ovarian Cancer

2006 ◽  
Vol 24 (26) ◽  
pp. 4254-4261 ◽  
Author(s):  
Keith L. Knutson ◽  
Christopher J. Krco ◽  
Courtney L. Erskine ◽  
Karin Goodman ◽  
Linda E. Kelemen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune System ◽  
T Cell ◽  
Cancer Patients ◽  
Folate Receptor ◽  
Prediction Algorithm ◽  
Amino Terminus ◽  
Folate Receptor Alpha ◽  
Receptor Alpha ◽  
Healthy Donors

Purpose Studies have demonstrated that the generation of immunity to tumor antigens is associated with improved prognosis for many cancers. A candidate antigen is the folate receptor alpha (FRα), which is overexpressed in breast and ovarian cancers. Our goal in this study was to attain a better understanding of the extent of endogenous FRα immunity. Methods Using a CD4+ T cell epitope prediction algorithm, we predicted promiscuous epitopes of FRα, and tested for immunity in 30 breast (n = 17) or ovarian (n = 13) cancer patients and 18 healthy donors using enzyme-linked immunospot analysis. Results Fourteen peptides were predicted, seven each from the carboxy- and amino-terminus halves of the protein. More than 70% of patients demonstrated immunity to at least one FRα peptide. Patients responded to an average of 3 ± 0.5 peptides, whereas healthy donors responded to 1 ± 0.4 peptides (P = .004). Five peptides were recognized by more than 25% of patients. Responses to three peptides were higher (P < .05) in patients than in healthy donors, suggesting augmented immunity. Compared with healthy individuals, patients developed higher immunity to the amino-terminus half of the receptor (P = .03). There was no difference between each group in the responses to nonspecific (P = .2) and viral stimuli (P = .5). Lastly, patients demonstrated elevated levels of FRα antibodies consistent with a coordinated immune response. Conclusion These findings demonstrate that the FRα is a target of the immune system in breast and ovarian cancer patients. Understanding which antigens are targeted by the immune system may be important for prognosis or immune-based therapies.

Abstract 657: Folate receptor alpha expression is associated with poor prognosis in patients with cervical cancer

2021 ◽  
Author(s):  
Shigemasa Takamizawa ◽  
Shu Yazaki ◽  
Yuki Kojima ◽  
Hiroshi Yoshida ◽  
Rui Kitadai ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Poor Prognosis ◽  
Folate Receptor ◽  
Folate Receptor Alpha ◽  
Receptor Alpha
Sign in / Sign up

Export Citation Format

Share Document